[ad_1]
In this episode of ETF Spotlight, I talk with Brad Loncar, CEO of Loncar Investments. Brad is in Chicago to attend the annual meeting of the ASCO (American Society of Clinical Oncology). It is the world's largest and most prestigious cancer conference, where participants learn about the latest developments in treating the disease.
Brad explains why ASCO is so important and how it uses it as an investor. According to him, Amgen (AMGN) is ASCO's most exciting biotech company this year with two very promising therapies – BiTE and KRAS.
The global market for cancer drugs is estimated at around $ 123 billion, and major players are investing heavily to take advantage of this increasingly competitive market. Pharmaceutical giant Bristol-Myers BMY, a pioneer in immunotherapy, acquires rival Celgene CELG for $ 74 billion.
Merck MRK acquires drug developer Peloton Therapeutics for $ 1.05 billion. The announcement took place while Peloton was preparing for his IPO. Earlier this year, Eli Lilly LLY bought Loxo Oncology for $ 8 billion.
Should we expect more mergers and acquisitions in space?
Brad has created the index for the CNCR Loncar Cancer Immunotherapy ETF, which invests in leading companies in research on immunotherapy. He explains why immunotherapy, which uses the immune system to fight cancer, is often referred to as a "game changer" for the treatment of cancer.
It also discusses important developments in space and the promising work being done by some smaller and innovative biotechnology companies.
Mirati Therapeutics MRTX, Iovance Biotherapeutics (formerly Lion Biotechnologies) IOVA and Nektar Therapeutics NKTR are in full swing. These are among the main CNCR operations. Learn more about them on the podcast.
WSJ recently announced that AstraZeneca AZN plans to target the early stages of the disease, while traditionally, pharmaceutical companies focus on drugs that treat advanced forms of cancer. Will the new approach help AstraZeneca to stand out from its competitors?
Health care is the weakest sector this year, mainly due to political concerns. Will the conference focus on policy issues?
Tune in the podcast to learn more.
Brad also created the CHNA Loncar China BioPharma ETF Index, which focuses on the booming biopharmaceutical industry in China. To learn more about these ETFs, please visit loncarfunds.com.
Please also visit the Institute of Cancer Research to learn more about this cancer treatment and clinical trials.
Make sure to be on the lookout for the next edition of Spotlight ETF! If you have comments or questions, please send an email to [email protected].
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Want to receive key information about ETFs directly in your inbox?"data-reactid =" 36 ">Want to receive key information about ETFs directly in your inbox?
Click to get this free report
& nbsp;
Eli Lilly and Company (LLY): Analysis Report Analysis of Free Shares
& nbsp;
AstraZeneca PLC (AZN): Free Stock Analysis Report
& nbsp;
Bristol-Myers Squibb Company (BMY): Free Shares Analysis Report Analysis
& nbsp;
Merck & amp; Co., Inc. (MRK): Free Stock Analysis Report
& nbsp;
Loncar ETF against Cancer Immunotherapy (CNCR): ETF Research Reports
& nbsp;
Celgene Corporation (CELG): Report of Analysis of Free Shares
& nbsp;
Mirati Therapeutics, Inc. (MRTX): Free Stock Analysis Report
& nbsp;
Amgen Inc. (AMGN): Report of Analysis of Free Shares
& nbsp;
Nektar Therapeutics (NKTR): Free Stock Analysis Report
& nbsp;
Lion Biotechnologies, Inc. (IOVA): Report of Analysis of Free Shares
& nbsp;
Loncar China BioPharma ETF (CHNA): ETF Research Reports
& nbsp;
To read this article on Zacks.com, click here.
& nbsp;
Zacks Investment Research"data-reactid =" 38 ">
Do you want to know the latest Zacks Investment Research recommendations? Today, you can download 7 best actions for the next 30 days. Click to get this free report
Eli Lilly and Company (LLY): Analysis Report Analysis of Free Shares
AstraZeneca PLC (AZN): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Shares Analysis Report Analysis
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Loncar ETF against Cancer Immunotherapy (CNCR): ETF Research Reports
Celgene Corporation (CELG): Report of Analysis of Free Shares
Mirati Therapeutics, Inc. (MRTX): Free Stock Analysis Report
Amgen Inc. (AMGN): Report of Analysis of Free Shares
Nektar Therapeutics (NKTR): Free Stock Analysis Report
Lion Biotechnologies, Inc. (IOVA): Report of Analysis of Free Shares
Loncar China BioPharma ETF (CHNA): ETF Research Reports
To read this article on Zacks.com, click here.
Zacks Investment Research
[ad_2]
Source link